East Asia Pharmaceuticals: Quetiapine API Approved for Registration in South Korea.

East Asia Pharmaceutical Announcement: The company recently received the registration certificate for the raw material of mosapride from the South Korea Food and Drug Administration. Mosapride raw material has a dual regulatory effect of promoting gastric motility insufficiency or inhibiting gastric motility excess, and can be used to treat symptoms caused by gastrointestinal motility disorders. The national sales of mosapride malate preparations in 2024 are approximately 372 million yuan. The company's mosapride raw material has obtained a registration certificate in South Korea, indicating that it has obtained access qualifications in South Korea, which will bring positive effects to the company's expansion of the South Korean pharmaceutical market and promote sales in other overseas markets.